







The Bern TAVI Registry 5-Year Small-Annuli Analysis¹

Okuno T, Tomii D, Lanz J, et al. 5-year outcomes with self-expanding vs balloon-expandable transcatheter aortic valve replacement in patients with small annuli. *JACC Cardiovasc Interv.* 2023;16(4):429-440.

Study design	Device(s) used	Distribution	Locations	Key patient demographics
 Propensity-matched registry comparing SAPIEN TAVI and CoreValve/Evolut TAVI (1:1) for patients with small annuli (<430 mm ² aortic annular area) N = 342 (total matched cohort)	  SAPIEN XT* , SAPIEN 3, and SAPIEN 3 Ultra valves CoreValve, Evolut R, Evolut PRO, and Evolut PRO+ valves	 Arm 1 (BEV): 100% <430 mm² aortic annular area Arm 2 (SEV): 100% <430 mm² aortic annular area	 Bern University Hospital (Bern, Switzerland)	 Female: BEV: 85.4% SEV: 84.2% Mean age: BEV 82.7 years SEV 82.2 years Mean STS score: BEV 5.34 SEV 5.15



*The SAPIEN XT valve has been discontinued not commercially available anymore

In a predominantly female, small annuli-only study:

- ✓ SAPIEN TAVI demonstrated significantly lower rates of disabling stroke than CoreValve/Evolut TAVI
- ✓ No improvement in mortality or reintervention associated with lower echo-derived gradients with self-expanding TAVI




SAPIEN TAVI delivers on critical outcomes for small-annuli patients




BEV=balloon-expandable valve; SEV=self-expanding valve; STS=Society of Thoracic Surgeons.

Rates of disabling stroke were significantly lower for SAPIEN TAVI through 5 years



SAPIEN TAVI delivers low rates of reintervention, despite higher PPM and echo-derived gradients ≥ 20 mmHg



“...it is noteworthy that the echocardiographic hemodynamic advantage of self-expanding THVs did not translate into a higher VARC-3 device success rate or improved clinical outcomes up to 5 years.” –Okuno et al, 2023

PPM=patient-prosthesis mismatch; VARC-3=Valve Academic Research Consortium-3.

TAVI: Transcatheter Aortic Valve Implantation

1. Okuno T, Tomii D, Lanz J, et al. 5-year outcomes with self-expanding vs balloon-expandable transcatheter aortic valve replacement in patients with small annuli. JACC Cardiovasc Interv. 2023;16(4):429-440.

Any quotations used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, SAPIEN, SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2025 Edwards Lifesciences Corporation. All rights reserved. PP--EU-9948 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards